Treatment of premenstrual syndrome

Journal of Medicinal Plant Research

Volumn 5, Issue 26, 2011, Pages 6122-6127

  Akram, Muhammad ^a   Akhtar, Naveed ^b   Asif, H M ^a   Shah, Pervaiz Akhtar ^c   Saeed, Tariq ^c   Mahmood, Arshad ^d   Malik, Nadia Shamshad ^e  

^a HAMDARD UNIVERSITY   (Pakistan)

^b THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^c UNIVERSITY OF THE PUNJAB   (Pakistan)

^d Tobe Camp University Road Abbottabad   (Pakistan)

^e UNIVERSITY OF LAHORE   (Pakistan)

Author keywords

Premenstrual syndrome; Research study; Treatment option

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPHA TOCOPHEROL; BENDROFLUMETHIAZIDE; BORAGE OIL; BROMOCRIPTINE; BUPLEURUM ROOT EXTRACT; CALCIUM; CHROMIUM; CITALOPRAM; DANAZOL; DIURETIC AGENT; DYDROGESTERONE; FLUOXETINE; GESTAGEN; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; LEVONORGESTREL; MAGNESIUM; MEFRUSIDE; NORETHISTERONE; OPIATE; PAEONIA RADIX; PAROXETINE; PROGESTERONE; PROSTAGLANDIN INHIBITOR; PYRIDOXINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ANXIETY; AYURVEDA; BREAST TENDERNESS; CHINESE MEDICINE; COGNITIVE THERAPY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EXERCISE; HERBAL MEDICINE; HOMEOPATHY; HUMAN; INDIGESTION; INSOMNIA; MASSAGE; MASTALGIA; MORNING DOSAGE; MUSCLE CRAMP; OVULATION; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; REFLEXOLOGY; RELAXATION TRAINING; REVIEW; SEROTONIN BRAIN LEVEL; SYMPTOM; VAGINA PESSARY;

EID: 82155163909     PISSN: None     EISSN: 19960875     Source Type: Journal    
DOI: 10.5897/JMPR11.1198     Document Type: Review

References (39)

1. Atmaca M, Kumru S, Tezcan E(2003). Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum, Psychopharmacol., 18(3): 191-195.
2. Auld WHR, Murdoch WR (1971). Clinical Trial of Mefruside, a New Diuretic, Br. Med. J., 4(5790): 786-788.
3. Bancroft J, Rennie D, Warner P (1994). Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom. Med., 56: 225-231.
4. Barrero AF, Herrador MM, Arteaga JF, Akssira M, Mellouki F, Belgarrabe A, Blazquez MA (2005). Chemical composition of the essential oils of Pistacia atlantica Desf. JEOR, 17(1): 52-54.
5. Blumenthal M, Goldberg A, Brinckmann J (2000). Herbal Medicine: Expanded Commission E Monographs. Austin, Am. Bot. Council, pp. 244-248.
6. Braverman PK (2007). Premenstrual syndrome and premenstrual dysphoric disorder. J. Pediatr. Adolesc. Gynecol., 20(1): 3-12.
7. Brown J, Brien PM, Marjoribanks J, Wyatt K (2009). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev., 15: (2):39-42
8. Chung KW, Kim H, Kwon DJ, Lim YT, Kim JH, Kim EJ, Kim JH, Lee JW(1996). The effect of treatment according to the clinical characteristics in patients with premenstrual syndrome. Korean J. Obstet. Gynecol., 39: 303-315.
9. Daugherty JE (1998). Treatment strategies for premenstrual syndrome. Am. Fam. Physician, 58: 183-92., 197-198.
10. Dhingra D, Sharma A (2006). Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Progr. Neuro-Psychopharmacol. Biol. Psychiatr., 30: 449-454.
11. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC (1998). Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA, 280: 1569-1575.
12. Ernst E (2005). Is homeopathy a clinically valuable approach? Trends in Pharmacol. Sci., 26(11): 547-548.
13. Facchinetti F, Fioroni L, Martignoni E, Sances G, Costa A, Genazzani AR(1994). Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome. Psychosom. Med., 56: 418-22.
14. Freeman EW, Sondheimer SJ, Rickels K (1997). Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull., 33: 303-309.
15. Freeman EW. (2010). Therapeutic management of premenstrual syndrome. Expert. Opin. Pharmacother., 11 (17): 2879-1889.
16. Halbreich U (1995). Menstrually related disorders: what we do know, what we only believe that we know, and what we know that we do not know. Crit. Rev. Neurobiol., 9: 163-175.
17. Halbreich U, Tworek H (1993). Altered serotenergic activity in women with dysphoric premenstrual syndromes. Int. J. Psychiatry Med., 23: 1-27.
18. Halima N (2004). Clinical evaluation of herbal medicine for female disorders, dysmenorrhoea and vaginal discharge, M. Phil thesis, Hamdard University, Karachi.
19. James W, Jennifer S (2007), Metoprolol succinate extended release/hydrochlorothiazide combination tablets, Vasc. Health Risk Manag., 3(3): 279-288.
20. Jeong BS, Lee C, Lee JH, Seo MK, Han OS, Kim CY (2001). Prevalence of Premenstrual Syndrome and Premenstrual Dysphoric. J. Korean Neuropsychiatr. Assoc., 40: 551-558.
21. Kawai T (1994). Anti-emetic principles of Magnolia obovata bark and Zingiber officinale rhizome. Planta Medica, 60: 17-20.
22. Klein-Laansma CT, Jansen JC, van Tilborgh AJ, Van der Windt DA, Mathie RT, Rutten AL (2010). Semi-standardised homeopathic treatment of premenstrual syndrome with a limited number of medicines: feasibility study, Homeopathy, 99(3): 192-204.
23. Kulkarni SK, Reddy DS (1996). Animal Behaviour Models for Testing Anti-anxiety Agents. Methods Find. Exp. Clin. Pharmacol., 18: 219-240.
24. Lopez LM, Kaptein AA, Helmerhorst FM (2009). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev., 15:(2): 65-67.
25. Katrina M, Paul W, Martin F, Paul W, Shaugn P (2002). Prescribing patterns in premenstrual syndrome. BMC, 2(4): 1472-6874.
26. Kest B, Palmese CA, Hopkins E, Adler M, Juni A(2001). Assessment of acute and chronic morphine dependence in male and female mice. Pharmacol. Biochem. Behav., 70: 149-156.
27. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Clavo D, Paladini AC(1997). Neuroactive flavonoids: new ligands for the benzodiazepine receptors. Phytomed., 5: 235-243.
28. Moline ML, Zendell SM (2005). Evaluating and managing premenstrual syndrome. Medscape Womens Health, 5: 1-16.
29. Mustafa T, Srivastava KT (1990). Ginger (Zingiber officinale) in Migraine Headache. J. Ethnopharmacol., 29: 267-273.
30. Nosal'ova G, Saab BR, Pashayan N, El CS (1992). Antitussive efficacy of the complex extract and the polysaccharide of marshmallow (Althaea officinalis L. var. Robusta). Pharm., 47: 224-226.
31. Paladini AC, Marder M, Viola H, Wolfman C, Wasowaki C, Medina JH (1999). Flavonoids and the central nervous system: from forgotten factors to potent anxiolytic compounds. J. Pharm. Pharmacol., 51: 519-526.
32. Schellenberg R (2001). Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study, B.M.J., 322(7279): 134-137.
33. Steven K (1997). Cuttlefish ink, Homeopathy Book, An introduction and Handbook, Churchil Livingstone, p. 236.
34. Thys S, Starkey P, Bernstein D, Tian J (1998). Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol., 179(2): 444-452.
35. Van Die, Bone KM, Burger HG, Reece JE, Teede HJ (2009). Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J. Altern. Complement. Med., 15(9): 1045-1048.
36. Whitehead WE, Busch CM, Heller BR (1986). Social learning influences on menstrual symptoms and illness behavior. Health Psychol., 5: 13-23.
37. Woods NF, Most A, Longenecker GD (1985). Major life events, daily stressors, and perimenstrual symptoms. Nurs. Res., 34: 263-267.
38. Wyatt K, Dimmock PW, O'Brien PM (2000). Premenstrual syndrome. In: Barton S, ed. Clinical evidence. 4th issue. London: BMJ Publishing Group, pp. 1121-1133.
39. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA., 278: 983-988.